Skip to main content

Troglitazone Pregnancy and Breastfeeding Warnings

Brand names: Rezulin

Troglitazone Pregnancy Warnings

Troglitazone has been assigned to pregnancy category B by the FDA. Animal studies have not revealed evidence of teratogenicity. Decreased body weight of offspring was demonstrated in rats receiving troglitazone. There are no controlled data in human pregnancy. Troglitazone is only recommended for use during pregnancy when benefit outweighs risk.

See references

Troglitazone Breastfeeding Warnings

There are no data on the excretion of troglitazone into human milk. Because many drugs are excreted into human milk, clinicians are encouraged to consider the potential risk of the drug to the nursing infant compared with the benefit of the drug to the mother.

See references

References for pregnancy information

  1. Product Information. Rezulin (troglitazone). Parke-Davis. 2001;PROD.

References for breastfeeding information

  1. Product Information. Rezulin (troglitazone). Parke-Davis. 2001;PROD.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.